Media stories about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 48.2352854882737 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Collegium Pharmaceutical, Inc. to Post FY2017 Earnings of ($2.45) Per Share, Gabelli Forecasts (COLL) (americanbankingnews.com)
- Collegium Pharmaceutical, Inc. (COLL) Expected to Post FY2017 Earnings of ($2.30) Per Share (americanbankingnews.com)
- FY2017 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Analyst (COLL) (americanbankingnews.com)
- Swinging Stocks: Whiting Petroleum Corporation (NYSE:WLL), Collegium Pharmaceutical, Inc. (NASDAQ:COLL … – The Stock Street (press release) (thestreetpoint.com)
- An Eye on Volatility – Collegium Pharmaceutical, Inc., (NASDAQ: COLL) – Stock Watch (stocksnewstimes.com)
A number of analysts have recently commented on the company. BidaskClub cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. HC Wainwright assumed coverage on Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 price target for the company. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Collegium Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $20.00.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. During the same period in the previous year, the firm earned ($1.13) EPS. Collegium Pharmaceutical’s quarterly revenue was up 2814.6% compared to the same quarter last year. research analysts anticipate that Collegium Pharmaceutical will post -2.63 earnings per share for the current fiscal year.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.